Table 3. Scores of MP-MRI with PI-RADS Categorized in Different PSA Levels.
| Score of PI-RADS | PSA 0.01–4.00 ng/ml | PSA 4.01–10.00 ng/ml | PSA >10.00 ng/ml | PSA unknown | Whole | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Biop-sied* | PCa** | Total | Biop-sied* | PCa** | Total | Biop-sied* | PCa** | Total | Biop-sied* | PCa** | Total | Biop-sied* | PCa** | |
| 1 | 66 | 10 | 0 | 167 | 54 | 3 | 139 | 65 | 2 | 34 | 2 | 0 | 406 | 131 | 5 |
| 2 | 36 | 5 | 0 | 58 | 18 | 2 | 35 | 19 | 1 | 6 | 0 | 0 | 135 | 42 | 3 |
| 3 | 16 | 8 | 2 | 36 | 16 | 7 | 53 | 33 | 17 | 4 | 1 | 0 | 109 | 58 | 26 |
| 4 | 10 | 4 | 1 | 57 | 31 | 21 | 110 | 88 | 64 | 1 | 0 | 0 | 178 | 123 | 86 |
| 5 | 4 | 4 | 3 | 27 | 23 | 22 | 250 | 204 | 194 | 4 | 1 | 1 | 285 | 232 | 220 |
| Total | 132 | 31 | 6 | 345 | 142 | 55 | 587 | 409 | 278 | 49 | 4 | 1 | 1113 | 586 | 340 |
MP-MRI: multiparametric magnetic resonance imaging; PI-RADS: Prostate Imaging Reporting and Data System; PSA: prostate specific antigen; PCa: prostate cancer.
* Only patients with biopsy within three months after prostate MP-MRI were included.
** Only patients, who were pathologically diagnosed with PCa by biopsy within three months after prostate MP-MRI, were included.
For 582 patients with baseline PSA level included for analysis, diagnostic efficacy of MP-MRI for the detection of PCa is presented in Table 4. Each groups showed excellent area under the curve (AUC) (0.88–0.91), suggesting obviously clinically relevant predictive characteristics. Also, MP-MRI showed a very high sensitivity (90.9%-100.0%) and excellent NPV (93.1%-100.0%) in each groups.